Somewhat Favorable News Coverage Somewhat Unlikely to Affect AbbVie (ABBV) Share Price

Media headlines about AbbVie (NYSE:ABBV) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.5713538734241 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

ABBV stock opened at $93.61 on Thursday. AbbVie has a 1-year low of $69.38 and a 1-year high of $125.86. The company has a market capitalization of $148.55 billion, a PE ratio of 16.72, a P/E/G ratio of 0.87 and a beta of 1.61. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.10 and a current ratio of 1.20.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Thursday, April 26th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.08. AbbVie had a return on equity of 186.47% and a net margin of 21.55%. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.60 billion. During the same period in the prior year, the company posted $1.28 EPS. The company’s revenue was up 21.4% compared to the same quarter last year. analysts forecast that AbbVie will post 7.8 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 15th. Stockholders of record on Friday, July 13th will be paid a $0.96 dividend. The ex-dividend date is Thursday, July 12th. This represents a $3.84 annualized dividend and a dividend yield of 4.10%. AbbVie’s dividend payout ratio is currently 68.57%.

Several equities analysts recently weighed in on ABBV shares. Deutsche Bank cut AbbVie from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $125.86 to $65.61 in a research report on Wednesday, May 30th. Deutsche Bank cut AbbVie from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $125.86 to $65.61 in a research report on Wednesday, May 30th. Goldman Sachs Group cut AbbVie from a “conviction-buy” rating to a “buy” rating in a research report on Thursday, May 24th. Piper Jaffray Companies cut AbbVie from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $125.86 to $66.62 in a research report on Friday, June 1st. Finally, BMO Capital Markets set a $95.00 price target on AbbVie and gave the company a “sell” rating in a report on Tuesday, March 13th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $105.85.

In other news, SVP Timothy J. Richmond sold 17,588 shares of the company’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $99.47, for a total value of $1,749,478.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward J. Rapp acquired 1,013 shares of the stock in a transaction dated Wednesday, June 20th. The stock was bought at an average price of $98.63 per share, for a total transaction of $99,912.19. The disclosure for this purchase can be found here. Corporate insiders own 0.07% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.

Leave a Reply